Davide Seripa
A5053361130- Alzheimer's disease research and treatments
- Dementia and Cognitive Impairment Research
- Cholinesterase and Neurodegenerative Diseases
- Genetic Associations and Epidemiology
- Frailty in Older Adults
- Pharmacogenetics and Drug Metabolism
- Schizophrenia research and treatment
- Computational Drug Discovery Methods
- Nutritional Studies and Diet
- Bipolar Disorder and Treatment
- Nutrition and Health in Aging
- Parkinson's Disease Mechanisms and Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Tryptophan and brain disorders
- Diet and metabolism studies
- Neuroinflammation and Neurodegeneration Mechanisms
- Genetics and Neurodevelopmental Disorders
- Folate and B Vitamins Research
- Fatty Acid Research and Health
- Hearing, Cochlea, Tinnitus, Genetics
- Amyotrophic Lateral Sclerosis Research
- Lipoproteins and Cardiovascular Health
- Treatment of Major Depression
- Bioinformatics and Genomic Networks
- Hearing Loss and Rehabilitation
Casa Sollievo della Sofferenza
2015-2024
Ospedale Vito Fazzi
2020-2024
Molecular Biology Consortium
2023
Istituti di Ricovero e Cura a Carattere Scientifico
2012-2021
Framingham Heart Study
2018-2020
John Wiley & Sons (United States)
2019
Hudson Institute
2019
Nuovo Ospedale San Giovanni di Dio
2008-2018
Boston University
2018
Institute for Neurodegenerative Disorders
2018
Our objective was to construct and validate a Multidimensional Prognostic Index (MPI) for 1-year mortality from Comprehensive Geriatric Assessment (CGA) routinely carried out in elderly patients geriatric acute ward. The CGA included clinical, cognitive, functional, nutritional, social parameters using six standardized scales information on medications support network, total of 63 items eight domains. A MPI developed data by aggregating the scores domains expressing it as score 0 1. Three...
Genetic discoveries of Alzheimer's disease are the drivers our understanding, and together with polygenetic risk stratification can contribute towards planning feasible efficient preventive curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets by-proxy results (discovery n = 409,435 validation size 58,190). Here, we add six variants associated (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 two exonic in SHARPIN gene). Assessment...
Background Frailty is a clinical syndrome generally associated with greater risk for adverse outcomes such as falls, disability, institutionalization, and death. Cognition dementia have already been considered components of frailty, but the role frailty possible determinant dementia, Alzheimer's disease (AD), vascular (VaD) has poorly investigated. We estimated predictive on incident its subtypes in nondemented, Italian, older population. Methods evaluated 2581 individuals recruited from...
Abstract Alzheimer’s disease (AD), the leading cause of dementia, has an estimated heritability approximately 70% 1 . The genetic component AD been mainly assessed using genome-wide association studies, which do not capture risk contributed by rare variants 2 Here, we compared gene-based burden damaging in exome sequencing data from 32,558 individuals—16,036 cases and 16,522 controls. Next to TREM2 , SORL1 ABCA7 observed a significant rare, predicted ATP8B4 ABCA1 with risk, suggestive signal...
Importance An estimated 40% of dementia is potentially preventable by modifying 12 risk factors throughout the life course. However, robust evidence for most these lacking. Effective interventions should target in causal pathway to dementia. Objective To comprehensively disentangle aspects modifiable Alzheimer disease (AD) inspire new drug targeting and improved prevention. Design, Setting, Participants This genetic association study was conducted using 2-sample univariable multivariable...